ArticleCurrent oncology (Toronto, Ont.)2010
KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies.
Article in Current oncology (Toronto, Ont.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment?World journal of gastrointestinal oncology · 2023Review
- ZNF24 regulates the progression of KRAS mutant lung adenocarcinoma by promoting SLC7A5 translation.Frontiers in oncology · 2022Article
- Predictive factors for distant recurrence of colorectal cancer in patients after curative resection for stage I-III colorectal cancer in Australia.Langenbeck's archives of surgery · 2021Article
- Identifying Novel Actionable Targets in Colon Cancer.Biomedicines · 2021Review
- Screening of important metabolites and KRAS genotypes in colon cancer using secondary ion mass spectrometry.Bioengineering & translational medicine · 2021Article
- Biomarkers and intermediate-high risk non-muscle invasive bladder cancer: a multivariate analysis of three different cellular pathways with pronostic implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Observational
- Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment.Frontiers in oncology · 2021Review
- Understanding Molecular Testing Uptake Across Tumor Types in Eight Countries: Results From a Multinational Cross-Sectional Survey.JCO oncology practice · 2020Article
- Histology and its prognostic effect onOncology letters · 2020Article
- IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL CANCER.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2020Article
- Mucinous Adenocarcinoma of the Rectum: A Whole Genome Sequencing Study.Frontiers in oncology · 2020Article
- Article
- Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.Journal of gastrointestinal cancer · 2019Article
- Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery withOncotarget · 2018Article
- Prognostic value ofCancer management and research · 2018Article
- HDAC-4 regulates claudin-2 expression in EGFR-ERK1/2 dependent manner to regulate colonic epithelial cell differentiation.Oncotarget · 2017Article
- Article
- Novel Approach for Clinical Validation of the cobas KRAS Mutation Test in Advanced Colorectal Cancer.Molecular diagnosis & therapy · 2016Article
- BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies.Journal of gastrointestinal oncology · 2015Review
- KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.Journal of experimental & clinical cancer research : CR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survival of patients with metastatic CRC (mCRC) has improved steadily over the past several decades, due largely to the development of new combinations of standard chemotherapy, as well as to the introduction of new targeted therapies. Among the available targeted therapies are two monoclonal antibodies that target the epidermal growth factor receptor (EGFR) - cetuximab and panitumumab - which have demonstrated efficacy in the treatment of mCRC. These therapies are associated with a unique set of toxicities and costs, prompting the need for tools to select patients who are most likely to derive a benefit from them. Mutations in the KRAS oncogene have consistently been shown to predict non-response to cetuximab and panitumumab. The role of KRAS as a marker of efficacy of anti-EGFR therapies is reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.